![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » U.S., Eli Lilly Forge Deal for COVID-19 Antibody Drug
U.S., Eli Lilly Forge Deal for COVID-19 Antibody Drug
![100Bills_flatmoney.gif](https://www.fdanews.com/ext/resources/test/Drug-Images3/100Bills_flatmoney.gif?t=1578960048&width=430)
October 29, 2020
Eli Lilly has landed a $375 million contract from the U.S. government to supply 300,000 vials of its investigational COVID-19 treatment, LY-CoV555 (bamlanivimab).
The FDA is currently reviewing Lilly’s application for Emergency Use Authorization of the neutralizing antibody as an early-stage treatment for high-risk patients.
Delivery will occur over two months, if approved, with an option for an additional 650,000 vials through the end of June 2021.
LY-CoV555 has shown mixed results so far in clinical trials. The National Institute of Allergy and Infectious Diseases has halted a trial of the antibody in combination with remdesivir after the trial’s independent data and safety monitoring board found no clinical benefit.
Upcoming Events
-
21Oct